Clinical, patient-reported, and radiographic outcomes of proximal humerus open reduction internal fixation augmented with calcium sulfate hydroxyapatite bio-composite (CERAMENT BONE VOID FILLER)

24 patients were enrolled in the study. 20 patients (83 %) were female. Mean age was 68±11 years and mean BMI was 29±7 kg/m². Patients had a mean follow up of 424±123 days. All patients had radiographic evidence of bone void filler resorption and remodeling at an average of 130±77 days. Of the 24 patients, 21 had available PROMIS scores. At final follow up, patients reported an average 46.3 ± 9.9 physical function score and 63.8 ± 6.3 pain interference score at an average of 273±191 days post operative. The 24 patients augmented with CBVF were matched to 24 patients with PHF without augmentation. Twenty-two patients in the CBVF group had fracture union compared to twenty in the non-augmented group(92 % vs 83 %, p = 0.38). Additionally, the CBVF group had reduced rates of screw penetration(4 % vs 21 %, p = 0.08), progressive fracture displacement(4 % vs 17 %, p = 0.16), and revision surgery(4 % vs 17 %, p = 0.16). On multivariate analysis, the use of CBVF significantly lowered the odds of developing intra-articular screw penetration(OR = 0.007, p = 0.02) CONCLUSION: This series demonstrates favorable outcomes in proximal humerus ORIF augmented using calcium sulfate hydroxyapatite bio-composite as bone void filler compared to a matched cohort of patients treated without augmentation. There is a low rate of loss of fracture fixation and high union rate with favorable patient reported outcome measures.